30493-41-5

Usage

Uses

Used in Pharmaceutical Research and Development:
Ethanone, 1-(6-bromoimidazo[1,2-a]pyridin-3-yl)-, is employed as a key component in the research and development of new pharmaceuticals. Its unique structure and reactivity make it a valuable candidate for the creation of novel drug molecules with potential therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Ethanone, 1-(6-bromoimidazo[1,2-a]pyridin-3-yl)-, serves as a building block for the synthesis of various bioactive compounds. Its chemical properties allow for the design and modification of drug candidates to improve their efficacy, selectivity, and safety profiles.
Used in Drug Discovery:
Ethanone, 1-(6-bromoimidazo[1,2-a]pyridin-3-yl)-, is utilized in drug discovery processes to identify and optimize potential drug candidates. Its presence in compound libraries facilitates high-throughput screening and structure-activity relationship studies, leading to the discovery of new therapeutic agents.
Used in Chemical Synthesis:
Ethanone, 1-(6-bromoimidazo[1,2-a]pyridin-3-yl)-, is also used in chemical synthesis for the preparation of various organic compounds. Its reactivity and functional groups enable the formation of diverse chemical products, which can be further explored for their potential applications in different industries.
Used in Analytical Chemistry:
In analytical chemistry, Ethanone, 1-(6-bromoimidazo[1,2-a]pyridin-3-yl)-, can be employed as a reference compound or a standard for the development and validation of analytical methods. Its unique chemical properties and structure make it suitable for use in chromatographic, spectroscopic, and other analytical techniques.
Used in Material Science:
Ethanone, 1-(6-bromoimidazo[1,2-a]pyridin-3-yl)-, may also find applications in material science, where its chemical and physical properties can be harnessed to develop new materials with specific characteristics. These materials could be used in various applications, such as sensors, catalysts, or advanced materials for electronic devices.

Upstream product

• 474706-74-6 6-bromo-3-iodoimidazo[1,2-a]pyridine 
• 97674-02-7 tributyl(1-ethoxyvinyl)stannane 
• 1072-97-5 5-bromo-2-pyridylamine 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 598-31-2 1-bromoacetone 
• 138240-34-3 (E)-N’-(5-bromopyridin-2-yl)-N,N-dimethylformamidine 
• 78-95-5 chloroacetone 

Downstream Products

• 1276110-10-1 N-(5-(3-(1H-pyrazol-3-yl)imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-benzenesulfonamide 
• 1276110-02-1 N-(5-(3-acetylimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide 

Relevant academic research and scientific papers

DERIVATIVES OF 4-(IMIDAZO[L,2-A]PYRIDIN-3-YL)-N-(PYRIDINYL)PYRIMIDIN- 2-AMINE AS THERAPEUTIC AGENTS

A novel class of heteroaryl compounds for use in the prevention and/or treatment of proliferative diseases and conditions including cancers. The compounds are considered to be capable of inhibiting cell proliferation by inhibiting the activity of FLT3 and its mutant forms and/or other protein kinases such as CDKs. The compounds have the general structure I:

Double (amino-sulfur generation of formic acid ) - 1,3-propane diester compound and its synthetic method, pharmaceutical composition and use thereof

The invention relates to a bis(aminodithioformate)-1,3-propane diester compound, and synthesis method thereof, a pharmaceutical composition containing the compound and a use, and especially relates to the use in preparing drugs for treating or preventing cancers. The compound is represented as the formula (I), wherein A is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclic group, R1 and R2 are the same or different and are independently selected from hydrogen, alkyl, aryl alkyl or heteroaryl alkyl, or a substituted or unsubstituted heterocyclic ring formed together by the R1, the R2 and an N atom connected with the R1 and the R2.

2,3-DISUBSTITUTED PYRIDINE COMPOUNDS AS TGF-BETA INHIBITORS AND METHODS OF USE

The invention described herein comprises compounds of formula (IV) and a method of treating cancer comprising administering to a subject having cancer one of the compounds in conjunction with another therapeutic treatment of cancer. The compounds (IV) inhibit signaling by a member of the TGF-β superfamily such as Nodal or Activin.

Inhibiting NF-κB-inducing kinase (NIK): Discovery, structure-based design, synthesis, structure-activity relationship, and co-crystal structures

The discovery, structure-based design, synthesis, and optimization of NIK inhibitors are described. Our work began with an HTS hit, imidazopyridinyl pyrimidinamine 1. We utilized homology modeling and conformational analysis to optimize the indole scaffol

THIOZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of PB kinases using thiozolidinedione derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of thiozolidinedione derivatives.

Synthesis and biological evaluation of imidazo[1,2-a]pyridine derivatives as novel PI3 kinase p110α inhibitors

3-{1-[(4-Fluorophenyl)sulfonyl]-1H-pyrazol-3-yl}-2-methylimidazo[1,2-a]pyridine, 2a, was discovered in our chemical library as a novel p110α inhibitor with an IC50 of 0.67 μM, through screening in a scintillation proximity assay. Optimization o